These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38750345)

  • 21. Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.
    Berrocal A; Arance A; Lopez Martin JA; Soriano V; Muñoz E; Alonso L; Espinosa E; Lopez Criado P; Valdivia J; Martin Algarra S;
    Melanoma Res; 2014 Dec; 24(6):577-83. PubMed ID: 25046550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
    Wolchok JD; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Lao CD; Cowey CL; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Butler MO; Hill A; Márquez-Rodas I; Haanen JBAG; Guidoboni M; Maio M; Schöffski P; Carlino MS; Lebbé C; McArthur G; Ascierto PA; Daniels GA; Long GV; Bas T; Ritchings C; Larkin J; Hodi FS
    J Clin Oncol; 2022 Jan; 40(2):127-137. PubMed ID: 34818112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
    Wu B; Shi L
    JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic Therapy for Melanoma: ASCO Guideline Update.
    Seth R; Agarwala SS; Messersmith H; Alluri KC; Ascierto PA; Atkins MB; Bollin K; Chacon M; Davis N; Faries MB; Funchain P; Gold JS; Guild S; Gyorki DE; Kaur V; Khushalani NI; Kirkwood JM; McQuade JL; Meyers MO; Provenzano A; Robert C; Santinami M; Sehdev A; Sondak VK; Spurrier G; Swami U; Truong TG; Tsai KK; van Akkooi A; Weber J
    J Clin Oncol; 2023 Oct; 41(30):4794-4820. PubMed ID: 37579248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia.
    Maeda T; Hiura A; Uehara J; Toyoshima R; Nakagawa T; Yoshino K
    Eur J Dermatol; 2021 Oct; 31(5):662-664. PubMed ID: 34642136
    [No Abstract]   [Full Text] [Related]  

  • 26. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
    Ascierto PA; Del Vecchio M; Mandalá M; Gogas H; Arance AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Márquez-Rodas I; Butler MO; Maio M; Middleton MR; de la Cruz-Merino L; Arenberger P; Atkinson V; Hill A; Fecher LA; Millward M; Khushalani NI; Queirolo P; Lobo M; de Pril V; Loffredo J; Larkin J; Weber J
    Lancet Oncol; 2020 Nov; 21(11):1465-1477. PubMed ID: 32961119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain.
    Rodríguez-Lescure A; de la Peña FA; Aranda E; Calvo A; Felip E; Garrido P; Vera R
    Clin Transl Oncol; 2020 Dec; 22(12):2253-2263. PubMed ID: 32533318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immune checkpoint inhibitors for treatment of advanced stage melanoma].
    Lupu J; Herrscher H; Robert C
    Rev Prat; 2020 May; 70(5):471-474. PubMed ID: 33058629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant vemurafenib in resected, BRAF
    Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
    Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
    Afzal MZ; Shirai K
    J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.
    Meng Y; Hertel N; Ellis J; Morais E; Johnson H; Philips Z; Roskell N; Walker A; Lee D
    Eur J Health Econ; 2018 Nov; 19(8):1163-1172. PubMed ID: 29524005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
    Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
    Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Fleeman N; Bagust A; Boland A; Beale S; Richardson M; Krishan A; Stainthorpe A; Abdulla A; Kotas E; Banks L; Payne M
    Pharmacoeconomics; 2017 Oct; 35(10):1035-1046. PubMed ID: 28316007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma.
    Gibson EJ; Begum N; Koblbauer I; Dranitsaris G; Liew D; McEwan P; Yuan Y; Juarez-Garcia A; Tyas D; Pritchard C
    J Med Econ; 2019 Jun; 22(6):531-544. PubMed ID: 30638416
    [No Abstract]   [Full Text] [Related]  

  • 35. Volume increase of spleen in melanoma patients undergoing immune checkpoint blockade.
    Susok L; Reinert D; Lukas C; Stockfleth E; Gambichler T
    Immunotherapy; 2021 Aug; 13(11):885-891. PubMed ID: 34229447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma.
    Mason R; Dearden HC; Nguyen B; Soon JA; Smith JL; Randhawa M; Mant A; Warburton L; Lo S; Meniawy T; Guminski A; Parente P; Ali S; Haydon A; Long GV; Carlino MS; Millward M; Atkinson VG; Menzies AM
    Pigment Cell Melanoma Res; 2020 Mar; 33(2):358-365. PubMed ID: 31587511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of PD-L1, PD-1, and CTLA-4 Expression in the Clinical Practice as Predictors of Response to Nivolumab and Ipilimumab in Monotherapy in Patients With Advanced Stage Melanoma.
    Santos-Briz A; Cañueto J; Carmen SD; Barrios B; Yuste M; Bellido L; Ludeña MD; Román C
    Am J Dermatopathol; 2021 Jun; 43(6):423-428. PubMed ID: 33395045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
    Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
    Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant Therapy of Melanoma.
    Tarhini AA
    Hematol Oncol Clin North Am; 2021 Feb; 35(1):73-84. PubMed ID: 33759774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).
    Piulats JM; Espinosa E; de la Cruz Merino L; Varela M; Alonso Carrión L; Martín-Algarra S; López Castro R; Curiel T; Rodríguez-Abreu D; Redrado M; Gomà M; Rullán AJ; Calvo González A; Berrocal-Jaime A
    J Clin Oncol; 2021 Feb; 39(6):586-598. PubMed ID: 33417511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.